ArticleOncogene2008
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Exploring the mechanisms and targets of proton pump inhibitors-induced osteoporosis through network toxicology, molecular docking, and molecular dynamics simulations.Frontiers in pharmacology · 2025Article
- Alternative Splicing: A Critical Regulator in Human Bone Biology and Tumor Progression.Research (Washington, D.C.) · 2025Review
- Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.The American journal of pathology · 2023Article
- The chromosome-scale genome assembly of the yellowtail clownfish Amphiprion clarkii provides insights into the melanic pigmentation of anemonefish.G3 (Bethesda, Md.) · 2023Article
- Nucleolar localization of the ErbB3 receptor as a new target in glioblastoma.BMC molecular and cell biology · 2022Article
- Bone secreted factors induce cellular quiescence in prostate cancer cells.Scientific reports · 2019Article
- Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.Cancer research · 2018Article
- Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum.Methods in molecular biology (Clifton, N.J.) · 2018Article
- BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.Neoplasia (New York, N.Y.) · 2018Article
- ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).PloS one · 2017Article
- Integrated miRNA and mRNA expression profiling of tension force-induced bone formation in periodontal ligament cells.In vitro cellular & developmental biology. Animal · 2015Article
- Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.Molecular & cellular proteomics : MCP · 2015Article
- An expression signature at diagnosis to estimate prostate cancer patients' overall survival.Prostate cancer and prostatic diseases · 2014Article
- Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.Clinical & experimental metastasis · 2014Article
- Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.The Prostate · 2013Article
- Function of alternative splicing.Gene · 2013Review
- ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease.Frontiers in cellular neuroscience · 2013Article
- Bone matrix osteonectin limits prostate cancer cell growth and survival.Matrix biology : journal of the International Society for Matrix Biology · 2012Article
- Aberrant expression of katanin p60 in prostate cancer bone metastasis.The Prostate · 2012Article
- Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.Oncogene · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 5 countries.
Funding
Abstract
ErbB3 is a transmembrane growth factor receptor that has been implicated in the pathogenesis of human cancer. After finding that a truncated form of ErbB3 was present and upregulated in metastatic prostate cancer cells in lymph nodes and bone, we explored the pathophysiological functions of this unusual form of ErbB3 in the context of mouse calvaria as well as osteoblasts in vitro and the femur microenvironment in vivo. Here we demonstrate that prostate cancer cells expressed an alternatively spliced transcript that encodes a 45-kDa glycosylated protein (p45-sErbB3). The recombinant p45-sErbB3 purified from conditioned medium stimulated calvarial bone formation and induced osteoblast differentiation. Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice. Further, we detected sErbB3 in plasma samples from patients with castration-resistant prostate cancer with bone metastasis. These observations establish that p45-sErbB3 is a structurally and functionally unique gene product of ErbB3 and suggest that p45-sErbB3 is likely one of the factors involved in the osteoblastic bone metastases of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.